Navigation Links
Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
Date:12/11/2007

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that interim results of physician-sponsored studies of clevudine for the treatment of chronic hepatitis B virus (HBV) and both preclinical and clinical results of R7128 for the treatment of chronic hepatitis C virus (HCV) will be presented at the Frontiers in Drug Development in Viral Hepatitis (HEP-DART) conference being held in Lahaina, Hawaii from December 9 - 13, 2007. The abstract titles and abbreviated study summaries are described below. The full conference abstracts are currently available for download in PDF format in the "Events & Presentations" section of Pharmasset's website at http://investor.pharmasset.com/events.cfm . The full scientific presentations will be available for download in PDF format following the conference in the "Product Pipeline" section of Pharmasset's website at http://www.pharmasset.com/pipeline .

Clevudine was Superior to Lamivudine in the Patients with HBeAg(+) Chronic Hepatitis B. GK Lau, et al.

Abstract Summary: The aim of this study is to compare the efficacy and safety of clevudine versus lamivudine for 48 weeks in chronic hepatitis B (CHB) e-antigen positive (HBeAg(+)) patients in a randomized and blinded manner. Based on the preliminary results from 22 patients (11 clevudine, 11 lamivudine), 48-weeks of dosing with clevudine 30mg showed superior viral suppression to lamivudine 100mg without the emergence of viral breakthrough in HBeAg(+) CHB patients. At week 48, serum HBV DNA levels were below the level of detection (<300 copies/mL) in 82% of patients in the cl
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)..., Dec. 1 TargeGen has announced th...rom a multi-center, US-based clinical,trial of TG...been scheduled at,the 2008 American Society of He...presentation are as follows:, Title: ...ailable, JAK2-Selective In...
(Date:12/1/2008)...study shows the Prox1 gene is a two-way switch tha...ls to be reprogrammed so that they lose their iden..., , MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNe...arch Hospital have discovered that a certain diffe...tity that it requires the constant expression of a...
(Date:12/1/2008)...ence Call Scheduled for Tuesday, December 9 at 11:...- , , SOUTH SAN FRANCISCO, Calif., Dec. 1 ...s, Inc. (Nasdaq: SNSS ), a biopharmaceutical com...ion of new oncology therapeutics, today announced ...eloid leukemia (AML) will be presented during the ...
(Date:11/30/2008)...Dec. 1 Abnormalities in... in children with autism spectrum disorder by usin...dy presented today at the annual meeting of the Ra..., "Using MEG, we can record the tiny magnetic f...said Timothy Roberts, Ph.D., vice chair of researc...
Breaking Medicine Technology:Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Northwest Secures US 241 0 Million Debt Financing 8035 1Northwest Secures US 241 0 Million Debt Financing 8035 2Northwest Secures US 241 0 Million Debt Financing 8035 3Northwest Secures US 241 0 Million Debt Financing 8035 4TorreyPines Therapeutics Reports Successful End of Phase II Meeting With FDA for Tezampanel 8033 1TorreyPines Therapeutics Reports Successful End of Phase II Meeting With FDA for Tezampanel 8033 2TorreyPines Therapeutics Reports Successful End of Phase II Meeting With FDA for Tezampanel 8033 3TorreyPines Therapeutics Reports Successful End of Phase II Meeting With FDA for Tezampanel 8033 4Invest in Kids Rally to Be Held Before St Louis Vice Presidential Debate 26966 1Invest in Kids Rally to Be Held Before St Louis Vice Presidential Debate 26966 2Maryland Stem Cell Commission Issues Requests for Applications 26961 1Maryland Stem Cell Commission Issues Requests for Applications 26961 2Maryland Stem Cell Commission Issues Requests for Applications 26961 3
(Date:12/1/2008)...TER, Minn. - Disturbing evidence of higher mortali...h mitral valve prolapse and severe leakage may be ...ion,s severity in women, according to findings of ...nnals of Internal Medicine . , Mitral valve prol...dwide and often requires cardiac surgery, preferab...
(Date:12/1/2008)...Walker Chooses Two Tampa Beneficiaries for Par and...TAMPA, Fla., Dec. 1 The...arity of Tampa Bay, Inc. and the Judeo Christian H...the 2009 Par and Poker Celebrity Challenge for Cha..., , "It is only appropriate that events lik...
(Date:12/1/2008)..., nicotine use, personality illnesses common, stud...ews) -- Psychiatric disorders are common among you...ment, a new report shows. , To reach this findi...5,000 respondents, aged 19 to 25, who took part in...Related Conditions. , The study found that 45.8...
(Date:12/1/2008)...TON, Dec. 1 Democratic ...ed the following statement commemorating World AID...http://www.newscom.com/cgi-bin/prnh/20080519/DNCLO...t World AIDS Day, and while we have made strides, ...ic with both a national and global strategy. We m...
Breaking Medicine News(10 mins):Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2Health News:Celebrity Event Gives Local Non-Profits a Reason to be Thankful 2Health News:Few Young Adults Seek Treatment for Psych Disorders 2
...n by surgeons who no longer stand by the patient, ... The International Journal of Medical Robotics and...urgeons and scientists have shown that the surgeon...le Internet connection. Robots are starting to pro...
...onmental Protection announced today that aerial sp...mosquito larvae in Philadelphia have been resched...oLex CG, which is not a chemical pesticide, but is...that targets mosquito and black fly larvae when ad...
...known as integrin alpha 7 (integrin 7) lead to unc...cer, report researchers at the University of Pitt...ed today in the Journal of the National Cancer Ins...a7 represents an important new target for cancer t...
...5N1 strain of bird flu has been detected among pou...n capital, officials said Wednesday. The virus w... Sungai Buloh area of Selangor state, said Kamarud...se control section at the Department of Veterinary...
Other Medicine News:Health News:Robotic Surgery A Cutting Edge in Medical Field 2Health News:Rescheduled: Aerial Mosquito Treatment for Philadelphia 2Health News:A New Target for Cancer Therapy-Integrin Alpha7 Molecule 2Health News:A New Target for Cancer Therapy-Integrin Alpha7 Molecule 3Health News:A New Target for Cancer Therapy-Integrin Alpha7 Molecule 4Health News:Bird Flu Reappears in Malaysia 2
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr
...he Nidek NM-200D's compact, lightweight body with ...more options to treat more patients, more comforta... operation and functionality for image capture, pr...ge data to the compact flash card. Through USB int...
PacePath is a comprehensive anatomic pathology software system that is the culmination of more than five years of development and testing by leading industry experts.
...abNet LIS is a Windows NT client server system tha...ity, power and high-speed volume required to meet ...ndustry experts, LabNet is structured to make gene...fective as possible. Our system can upload lab act...
Medicine Products: